PRS15 A Cost-Utility Analysis of Dacomitinib As First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 21 L858R Substitution Mutation in China
Abstract
Authors
G. Jin J. Zhao L. Luan P. Dong L. Yang